The announcement of PrARAZLO's availability through BC PharmaCare is likely to have a positive impact on Bausch Health's stock in the short term. This expansion into all public drug plans in Canada not only broadens the potential customer base but also enhances the company's dermatology portfolio's visibility and accessibility. The unique formulation of PrARAZLO, aimed at reducing side effects, positions it as a potentially preferred option for acne treatment, which could lead to increased adoption and sales. Given the prevalence of acne in Canada and the importance of diversified treatment options, this development is significant for Bausch Health.